Starpharma

Starpharma has become aware of fraudulent (scam) job postings that falsely claim to be related to US-based positions for Starpharma, including through CareerBuilder.com. We would like to clarify that we are not currently hiring for any roles outside of Australia.

Starpharma is pleased to share its Annual Report for 2024, which provides an overview of our business activities during the financial year. With the progress made in FY24, our current key focus remains on executing and delivering on our strategic priorities, which include licensing a DEP® clinical asset, advancing our radiopharmaceuticals program and our partnerships, and increasing revenue from our commercialised products.   View Starpharma’s Annual Report 2024 on our website today at www.starpharma.com. #Starpharma #Biotechnology #Healthcare #AusBiotech #Dendrimers #DendrimerTechnology #Science

A truly collaborative approach to addressing a serious public health issue: Together with University of Technology Sydney, UNSW RNA Institute, Garvan Institute of Medical Research, Biointelect Pty Ltd, NSW Medical Research and Starpharma, CSIRO is working to develop an mRNA vaccine for urinary tract infections (UTIs). UTIs represent a pervasive and significant health challenge and have a staggering impact on public health (250,000 Australians contract a UTI every year), especially as they become increasingly resistant to the drugs designed to kill them. https://lnkd.in/gTN9QrKN #AMR #UTIs #antimicrobialresistance #antibioticresistance

So excited to see where this $1.8M MRFF grant will take us in pioneering an mRNA vaccine against UTIs! UTIs represent a pervasive and significant health challenge and have a staggering impact on public health and healthcare costs worldwide., especially as they become increasingly drug-resistant. Approximately 250,000 Australians develop a UTI each year, and around 150 million people globally are affected. We’re working with University of Technology Sydney, UNSW RNA Institute, Garvan Institute of Medical Research Biointelect Pty Ltd, NSW Medical Research, and Starpharma to address this serious health issue. https://lnkd.in/gTN9QrKN Australian Government Department of Health and Aged Care

Urinary tract infections are extremely common and getting harder to treat due to antimicrobial resistance #AMR. Approximately a quarter of these infections are now resistant to the first type of #antibiotics that would usually be prescribed. Bacterial #Vaccines have an important role in helping to prevent infection and thereby reduce the need for #antibiotics. This grant will develop an accelerated workflow for an mRNA #vaccine for UTIs (and other bacterial pathogens). We are delighted to have brought together this team with expertise that spans fundamental and clinical #research, manufacturing, and market access, and patient insights. #convenor #nationalcollaborator Minimising AMR CSIRO University of Technology Sydney UNSW NSW Medical Research Garvan Institute of Medical Research Biointelect Pty Ltd Starpharma Australian Patient Advocacy Alliance

This week, we had the pleasure of hosting Dr. Mehdi Shahidi, CEO of Petalion Therapeutics and Venture Partner at Medicxi, and Shyam Masrani, Principal at Medicxi and Board representative of Petalion, at Starpharma. Earlier this year, Starpharma and Medicxi partnered to form Petalion Therapeutics, a new asset-centric company focusing on developing a novel cancer therapy using Starpharma’s #dendrimer technology. It was exciting to connect with Mehdi and Shyam in person and discuss the #Petalion project. 🌟

Last week, Dr Jeremy Paull, our VP of Development and Regulatory, represented Starpharma and its collaborators from The University of Queensland, UQ Centre for Advanced Imaging, Australian Institute for Bioengineering and Nanotechnology AIBN, and ARC Research Hub for Advanced Manufacture of Targeted Radiopharmaceuticals at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) Annual Meeting. He presented a scientific poster highlighting the advantages of Starpharma's #dendrimer technology in #radiopharmaceuticals. 🔬 Starpharma's radiopharmaceuticals development program has yielded promising results, showing that DEP dendrimers have great potential as a versatile and multifunctional platform for customising precision radiopharmaceuticals for #cancer imaging and therapeutic applications. Learn more about Starpharma at www.starpharma.com

Discover more from #ASCO24! 🌟 Dr Jia (Jenny) Liu shared insights with Video Journal of Oncology (VJOncology) on Starpharma’s promising Phase 1/2 clinical trial of DEP SN38 (DEP irinotecan). The trial results, highlighted during an oral podium presentation at the 2024 ASCO Annual Meeting, showed promising anti-cancer efficacy and tolerability in very late-stage patients who were heavily pre-treated. Watch it on VJ Oncology. 📺 #CancerResearch #ClinicalTrials #Oncology #Starpharma

Thrilled to share results from the Phase I/II clinical trial of dendrimer SN38 - Jia (Jenny) Liu Starpharma Stephanie Edmondson Jeremy Paull The Kinghorn Cancer Centre St Vincent’s Health Network Sydney Rasha Cosman Anthony Joshua https://lnkd.in/eqp6W4EP #ASCO24 #Cancer #ClinicalTrial #ColorectalCancer #OncoDaily #Oncology

🌟 Looking back on #ASCO24, it was an incredible opportunity to share Starpharma’s Phase 2 clinical trial results on both DEP® cabazitaxel and DEP® irinotecan with the global #oncology community. Professor James Spicer and Dr Jia (Jenny) Liu delivered truly compelling oral presentations, for which we are extraordinarily grateful. Thank you to James and Jenny, and to all other investigators and site support staff for their dedicated and invaluable role in Starpharma’s Phase 2 clinical programs. We also extend our heartfelt appreciation to the patients and their caregivers for their selfless contribution to cancer research.   #ASCO24 #CancerResearch #Innovation #HealthcareExcellence